Please login to the form below

Not currently logged in
Email:
Password:

decitabine

This page shows the latest decitabine news and features for those working in and with pharma, biotech and healthcare.

Merck strengthens KRAS stake with Taiho and Astex partnership

Merck strengthens KRAS stake with Taiho and Astex partnership

Taiho and Astex are already in a partnership for two oncology candidates – ASTX727 (cedazuridine and decitabine) and SGI-110 (guadecitabine).

Latest news

  • Pfizer gets first FDA nod for hedgehog inhibitor in AML Pfizer gets first FDA nod for hedgehog inhibitor in AML

    And in a bumper day for the therapeutic category, the FDA also approved AbbVie and Roche’s Venclexta (venetoclax) with cytarabine or a hypomethyelating agent (azacitidine or decitabine) for the exact

  • Otsuka to buy cancer biopharma Astex Otsuka to buy cancer biopharma Astex

    Astex' lead product is Dacogen (decitabine), which is approved for the treatment of myelodysplastic syndromes and for acute myeloid leukaemia (AML) in patients over 65 years of age.

  • Cancer data presented at ASCO

    Elsewhere, Eisai presented data concerning a phase III study of DNA methylation inhibitor Dacogen (decitabine) for injection in acute myeloid leukaemia (AML).

  • J&J positive about pipeline

    this month; and Dacogen (decitabine), currently sold as a treatment for myelodysplastic syndromes, for the new indication of acute myeloid leukaemia.

  • The Pump House

    RECENTLY LAUNCHED products. Generic name. Trade name (company). Indication. Country. Decitabine.

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The FDA also approved AbbVie and Roche’s Venclexta (venetoclax) with cytarabine or a hypomethylating agent (azacitidine or decitabine) for the exact same indication – adding to the options for this patient

  • Pharma deals during September 2013 Pharma deals during September 2013

    Astex' lead product is Dacogen (decitabine) for myelodysplastic syndromes (MDS). It was also recently approved for acute myeloid leukaemia (AML) in patients over 65 years of age in Europe.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...

Infographics